Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hematological immune related adverse events after treatment with immune checkpoint inhibitors.
Kramer R, Zaremba A, Moreira A, Ugurel S, Johnson DB, Hassel JC, Salzmann M, Gesierich A, Weppler A, Spain L, Loquai C, Dudda M, Pföhler C, Hepner A, Long GV, Menzies AM, Carlino MS, Sachse MM, Lebbé C, Baroudjian B, Enokida T, Tahara M, Schlaak M, Hayani K, Bröckelmann PJ, Meier F, Reinhardt L, Friedlander P, Eigentler T, Kähler KC, Berking C, Zimmer L, Heinzerling L. Kramer R, et al. Among authors: zaremba a. Eur J Cancer. 2021 Apr;147:170-181. doi: 10.1016/j.ejca.2021.01.013. Epub 2021 Mar 9. Eur J Cancer. 2021. PMID: 33706206
Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses.
Bayerl F, Meiser P, Donakonda S, Hirschberger A, Lacher SB, Pedde AM, Hermann CD, Elewaut A, Knolle M, Ramsauer L, Rudolph TJ, Grassmann S, Öllinger R, Kirchhammer N, Trefny M, Anton M, Wohlleber D, Höchst B, Zaremba A, Krüger A, Rad R, Obenauf AC, Schadendorf D, Zippelius A, Buchholz VR, Schraml BU, Böttcher JP. Bayerl F, et al. Among authors: zaremba a. Immunity. 2023 Jun 13;56(6):1341-1358.e11. doi: 10.1016/j.immuni.2023.05.011. Immunity. 2023. PMID: 37315536 Free article.
Database for queries of melanoma cohorts with molecular and clinical data.
Philip M, Puppel SH, Stiller M, Paschen A, Roesch A, Zaremba A, Schadendorf D, Horn S. Philip M, et al. Among authors: zaremba a. Pigment Cell Melanoma Res. 2023 Mar;36(2):252-258. doi: 10.1111/pcmr.13075. Epub 2022 Dec 7. Pigment Cell Melanoma Res. 2023. PMID: 36382970
A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task.
Brinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, Haferkamp S, Schadendorf D, Fröhling S, Utikal JS, von Kalle C; Collaborators. Brinker TJ, et al. Eur J Cancer. 2019 Apr;111:148-154. doi: 10.1016/j.ejca.2019.02.005. Epub 2019 Mar 8. Eur J Cancer. 2019. PMID: 30852421 Free article.
Clinical and genetic analysis of melanomas arising in acral sites.
Zaremba A, Murali R, Jansen P, Möller I, Sucker A, Paschen A, Zimmer L, Livingstone E, Brinker TJ, Hadaschik E, Franklin C, Roesch A, Ugurel S, Schadendorf D, Griewank KG, Cosgarea I. Zaremba A, et al. Eur J Cancer. 2019 Sep;119:66-76. doi: 10.1016/j.ejca.2019.07.008. Epub 2019 Aug 14. Eur J Cancer. 2019. PMID: 31419753 Free PMC article.
GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma.
Livingstone E, Zaremba A, Horn S, Ugurel S, Casalini B, Schlaak M, Hassel JC, Herbst R, Utikal JS, Weide B, Gutzmer R, Meier F, Koelsche C, Hadaschik E, Sucker A, Reis H, Merkelbach-Bruse S, Siewert M, Sahm F, von Deimling A, Cosgarea I, Zimmer L, Schadendorf D, Schilling B, Griewank KG. Livingstone E, et al. Among authors: zaremba a. Br J Dermatol. 2020 Nov;183(5):928-939. doi: 10.1111/bjd.18947. Epub 2020 Apr 13. Br J Dermatol. 2020. PMID: 32064597
[Immunotherapy for malignant melanoma].
Zaremba A, Zimmer L, Griewank KG, Ugurel S, Roesch A, Schadendorf D, Livingstone E. Zaremba A, et al. Internist (Berl). 2020 Jul;61(7):669-675. doi: 10.1007/s00108-020-00812-1. Internist (Berl). 2020. PMID: 32462249 Review. German.
Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report.
Matull J, Livingstone E, Wetter A, Zimmer L, Zaremba A, Lahner H, Schadendorf D, Ugurel S. Matull J, et al. Among authors: zaremba a. Front Oncol. 2020 Nov 11;10:592609. doi: 10.3389/fonc.2020.592609. eCollection 2020. Front Oncol. 2020. PMID: 33262949 Free PMC article.
137 results